Targeted Medical Pharma, Inc.

The stock remains in a deep long-term downtrend and sits far below its 200-day average, with the share price pinned near the 52-week low. That regime signals persistent technical weakness rather than a base-building pattern.

There is no analyst coverage, no consensus target, and no recent rating change pattern. The setup is effectively unloved and unpriced by the Street, so shareholders should watch for any future coverage or target initiation to reset expectations.

Earnings have not produced a beat in the last eight reported quarters, with a 0/8 record. No estimate trend is available, so the key watchpoint is whether revenue and margins stabilize enough to interrupt the long run of flat reported EPS outcomes.

No discretionary insider buying or selling is evident. The historical transactions are award-based grants, which are compensation-related rather than a conviction signal, so they do not change the read on management sentiment.

Profitability remains weak despite a 60.2% gross margin, with a -28.48% operating margin and -57.86% net margin. Revenue fell 9% year over year, and the balance sheet is stretched with $5.29 million of debt against just $82,643 of cash.

The company operates in specialty and generic pharmaceuticals, where scale and balance-sheet strength matter. Versus the sector, it looks financially weaker and far less liquid, while the valuation remains extremely depressed at a microcap market cap of $302.